Innoviva Net Income 2006-2020 | INVA

Innoviva net income from 2006 to 2020. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Innoviva Annual Net Income
(Millions of US $)
2019 $157
2018 $395
2017 $134
2016 $60
2015 $-19
2014 $-168
2013 $-171
2012 $-19
2011 $-115
2010 $-84
2009 $-85
2008 $-94
2007 $-160
2006 $-166
2005 $-143
Innoviva Quarterly Net Income
(Millions of US $)
2020-06-30 $77
2020-03-31 $65
2019-12-31 $46
2019-09-30 $40
2019-06-30 $38
2019-03-31 $34
2018-12-31 $264
2018-09-30 $47
2018-06-30 $55
2018-03-31 $30
2017-12-31 $58
2017-09-30 $24
2017-06-30 $35
2017-03-31 $17
2016-12-31 $25
2016-09-30 $15
2016-06-30 $15
2016-03-31 $4
2015-12-31 $4
2015-09-30 $-5
2015-06-30 $-8
2015-03-31 $-11
2014-12-31 $-16
2014-09-30 $-21
2014-06-30 $-64
2014-03-31 $-68
2013-12-31 $-50
2013-09-30 $-47
2013-06-30 $-36
2013-03-31 $-37
2012-12-31 $-31
2012-09-30 $-35
2012-06-30 $-37
2012-03-31 $85
2011-12-31 $-37
2011-09-30 $-31
2011-06-30 $-25
2011-03-31 $-23
2010-12-31 $-19
2010-09-30 $-21
2010-06-30 $-21
2010-03-31 $-23
2009-12-31 $-22
2009-09-30 $-22
2009-06-30 $-22
2009-03-31 $-19
2008-12-31 $-16
2008-09-30 $-21
2008-06-30 $-27
2008-03-31 $-30
2007-12-31 $-33
2007-09-30 $-32
2007-06-30 $-45
2007-03-31 $-49
2006-12-31 $-38
2006-09-30 $-38
2006-06-30 $-41
2006-03-31 $-49
2005-12-31 $-42
2005-09-30 $-38
2005-06-30 $-32
2005-03-31 $-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.100B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $380.285B 18.12
Roche Holding AG (RHHBY) Switzerland $307.223B 0.00
Merck (MRK) United States $208.991B 14.91
Novartis AG (NVS) Switzerland $200.147B 15.56
Pfizer (PFE) United States $200.048B 12.50
Novo Nordisk (NVO) Denmark $163.423B 26.59
AbbVie (ABBV) United States $153.788B 9.37
AstraZeneca (AZN) United Kingdom $146.073B 28.40
Eli Lilly (LLY) United States $143.289B 21.87
Sanofi (SNY) $126.734B 15.06
GlaxoSmithKline (GSK) United Kingdom $94.797B 12.43
Bayer (BAYRY) Germany $59.441B 8.57
H Lundbeck (HLUYY) Denmark $6.468B 11.24